30 completed. 30 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 30 |
| Phase 1 | 6 | Completed 6 |
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) Tuvusertib (M1774), Niraparib, Lartesertib (M4076) - Ovarian Cancer | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 63 | 2024-10-30 | 2026-09-14 |
| Niraparib Efficacy in Patient With Unresectable Mesothelioma Niraparib Oral Product, Active Symptom Control - Mesothelioma, Malignant | Phase 2 | Completed | University Hospital Southampton NHS Foundation Trust | 88 | 2022-07-11 | 2025-05-15 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Azenosertib, Niraparib - Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 117 | 2022-01-27 | 2026-03-18 |
| Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. Niraparib, Anlotinib - Platinum-resistant Recurrent Clear Cell Ovarian Cancer | Phase 2 | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 6 | 2021-12-15 | 2023-01-31 |
| Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer Dostarlimab, Niraparib - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 22 | 2020-12-28 | 2026-09-03 |
| Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC Niraparib, Dostarlimab - Head and Neck Cancer | Phase 2 | Completed | Trisha Wise-Draper | 10 | 2020-11-04 | 2026-05-07 |
| A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Niraparib Pill - Prostate Adenocarcinoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 11 | 2020-10-19 | 2026-03-04 |
| A Study of Niraparib in Patients With Relapsed Ovarian Cancer ZL-2306(Niraparib） - Ovarian Cancer | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 15 | 2020-08-04 | 2022-08-29 |
| Niraparib + Dostarlimab + RT in Pancreatic Cancer Niraparib, Dostarlimab, Radiation - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 2 | Completed | Massachusetts General Hospital | 18 | 2020-07-23 | 2025-08-15 |
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) Niraparib, Aromatase Inhibitors - Breast Cancer, Breast Cancer Metastatic | Phase 2 | Completed | MedSIR | 14 | 2020-06-15 | 2024-02-16 |
| Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting Niraparib - Ovarian Cancer | Phase 2 | Completed | The University of Hong Kong | 20 | 2020-05-01 | 2023-12-15 |
| Trial of Maintenance With Niraparib- Uterine Serous Carcinoma Niraparib - Endometrial Cancer, Papillary Serous Endometrial Carcinoma | Phase 2 | Completed | Northwell Health | 22 | 2019-12-30 | 2025-08-19 |
| Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) Niraparib plus Cabozantinib - Urothelial Cancer | Phase 1 / Phase 2 | Completed | Fundacion CRIS de Investigación para Vencer el Cáncer | 67 | 2019-10-14 | 2024-12-31 |
| Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | NRG Oncology | 22 | 2019-10-08 | 2026-07-10 |
| Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy Niraparib, Best supportive care - Urothelial Carcinoma | Phase 2 | Completed | University of Turin, Italy | 58 | 2019-08-27 | 2022-05-23 |
| Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma Rucaparib, Abemaciclib, pembrolizumab & bemcentinib - Mesothelioma, Malignant | Phase 2 | Completed | University of Leicester | 186 | 2019-01-28 | 2026-08-17 |
| Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer Niraparib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Takeda | 19 | 2018-12-28 | 2024-06-07 |
| Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer Niraparib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Takeda | 20 | 2018-12-26 | 2024-07-16 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Ganetespib, Niraparib, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 122 | 2018-11-30 | 2025-06-11 |
| A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer Niraparib, TSR-042, Bevacizumab - Ovarian Neoplasms | Phase 2 | Completed | Tesaro, Inc. | 77 | 2018-11-15 | 2025-07-15 |
Showing 20 of 30. Sign in to see all of them.
Ovarian Neoplasms (13) · Fallopian Tube Neoplasms (5) · Neoplasms (3) · Pancreatic Neoplasms (3) · Breast Neoplasms (2) · Mesothelioma (2) · Mesothelioma, Malignant (2) · Prostatic Neoplasms (2) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Recurrence (1)
Tesaro, Inc. (6) · Takeda (2) · Abramson Cancer Center at Penn Medicine (1) · Dana-Farber Cancer Institute (1) · EMD Serono Research & Development Institute, Inc. (1) · Fundacion CRIS de Investigación para Vencer el Cáncer (1) · Janssen Research & Development, LLC (1) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · MedSIR (1) · NRG Oncology (1) · Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1) · Northwell Health (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
United States (19) · Spain (5) · Canada (4) · France (4) · United Kingdom (4) · Belgium (3) · Denmark (3) · Italy (3) · Australia (2) · China (2) · Germany (2) · Israel (2) · Japan (2) · Netherlands (2) · Austria (1)
Albert Font, MD (1) · Antonio Llombart (1) · Daniel Castellano, MD (1) · Dean Fennell (1) · Dean Fennell, PhD, FRCP (1) · Ge Lou (1) · Hong Zheng (1) · Hongmin Pan (1) · James Cleary, MD, PhD (1) · Julie L Koenig, MD (1) · Ka Yu Tse, FRCOG (1) · Lingying Wu (1) · M. D Michaelson (1)
PMID 31194225, PMID 31194228, PMID 31375879, PMID 31474354, PMID 32193378, PMID 33327047, PMID 33470063, PMID 33515503, PMID 35131040, PMID 35157829, PMID 35443252, PMID 35810751, PMID 37185961, PMID 37404070, PMID 37993149, PMID 38427930, PMID 38702828, PMID 38754056, PMID 39019698, PMID 39058367, PMID 39244209, PMID 39251349, PMID 39626160, PMID 40016438, PMID 40602355
2017 (3), 2016 (1), U10CA180868 (1)